Effects of delafloxacin: A Synthesis of Findings from 27 Studies

  1. Home
  2. Effects of delafloxacin
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of delafloxacin: A Synthesis of Findings from 27 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of delafloxacin: A Synthesis of Findings from 27 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Delafloxacin is a new fluoroquinolone antibiotic that has been shown to be effective against a wide range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pneumoniae. 11 、 4 、 20 、 16 、 7 Studies have shown that delafloxacin is effective in treating various bacterial infections, including skin infections, pneumonia, and gonorrhea. 26 、 6 、 18 、 15 、 12 Delafloxacin has also been shown to be more potent than other fluoroquinolones in acidic environments, which are commonly found in infection sites. 3 、 21 This suggests that delafloxacin may be more effective in treating infections in these areas.

Benefits and Risks

Benefit Summary

Delafloxacin has been shown to be effective in treating various bacterial infections, including skin infections, pneumonia, and gonorrhea. 26 、 6 、 18 、 15 、 12 It has also been shown to be more potent than other fluoroquinolones in acidic environments, which are commonly found in infection sites. 3 、 21 This suggests that delafloxacin may be more effective in treating infections in these areas. Delafloxacin has been shown to have a favorable safety profile, with a low risk of QTc prolongation. 1 This suggests that delafloxacin may be a safer drug than other fluoroquinolones.

Risk Summary

Delafloxacin, like other fluoroquinolones, can have side effects. 、 9 These side effects can include nausea, vomiting, diarrhea, headache, and dizziness. 1 Delafloxacin may also increase the risk of tendon rupture. It is important to talk to your doctor about these risks before taking delafloxacin. Delafloxacin, like other antibiotics, can contribute to the development of antibiotic resistance. 21 It is important to take delafloxacin as prescribed by your doctor to minimize the risk of resistance.

Comparison Between Studies

Similarities Between Studies

The studies reviewed here all demonstrate the efficacy of delafloxacin in treating various bacterial infections. 11 、 4 、 20 、 16 、 7 Additionally, several studies indicate that delafloxacin exhibits improved potency in acidic environments, which is common in many infection sites. 3 、 21 This suggests that delafloxacin might be more effective in treating infections in these specific areas.

Differences Between Studies

These studies provide a detailed picture of delafloxacin’s potential efficacy in different infection sites. 6 、 4 、 12 For instance, delafloxacin has been shown to be effective in treating pneumonia. 6 It has also been demonstrated to be effective in treating skin infections. 26 、 18 While these studies suggest delafloxacin’s potential in treating various infections, the degree of its effectiveness can vary depending on the type and severity of the infection.

Consistency and Contradictions of Results

Research consistently indicates that delafloxacin shows effectiveness against a wide range of bacterial infections. 11 、 4 、 20 、 16 、 7 Studies also consistently point to delafloxacin’s enhanced potency in acidic environments, which is prevalent in many infection sites. 3 、 21 However, there are also consistent reports of side effects associated with delafloxacin, similar to other fluoroquinolones. 、 9 These side effects can include nausea, vomiting, diarrhea, headache, and dizziness. 1 Delafloxacin may also increase the risk of tendon rupture. It is important to consult with your doctor about these risks before taking delafloxacin.

Points to Consider in Real-World Application

Delafloxacin shows promise as an effective treatment for various bacterial infections. 11 、 4 、 20 、 16 、 7 However, like other fluoroquinolones, it poses the risk of side effects. 、 9 These side effects can include nausea, vomiting, diarrhea, headache, and dizziness. 1 Delafloxacin may also increase the risk of tendon rupture. It’s crucial to discuss these risks with your doctor before taking delafloxacin. Additionally, taking delafloxacin as prescribed by your doctor is essential to minimize the risk of antibiotic resistance.

Limitations of Current Research

Research on delafloxacin is still limited. 21 Further research is needed to understand the long-term effects of delafloxacin and how it affects different ethnicities and age groups. 2 More studies are required to understand delafloxacin’s interactions with other drugs.

Future Research Directions

Further research is necessary to gain a more thorough understanding of delafloxacin’s safety and efficacy. 21 Specifically, research should investigate the long-term effects of delafloxacin, how it impacts different ethnicities and age groups, and its interactions with other drugs. 2

Conclusion

Delafloxacin has shown promise as a potentially effective treatment for various bacterial infections. 11 、 4 、 20 、 16 、 7 However, like other fluoroquinolones, it poses risks of side effects. 、 9 Consult your doctor to discuss these risks before taking delafloxacin. 1 Remember, delafloxacin is still under investigation, and further research is required for a comprehensive understanding of its potential benefits and limitations.

Literature analysis of 27 papers
Positive Content
25
Neutral Content
1
Negative Content
1
Article Type
5
0
1
10
27
1.

A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.

Author: LitwinJeffrey S, BenedictMichael S, ThornMichael D, LawrenceLaura E, CammarataSue K, SunEugene

Treatment of bacterial infections
Adverse events
QTc prolongation

Delafloxacin, given intravenously at 300 mg or 900 mg, did not prolong the QTc interval in healthy adults. The study found no relationship between delafloxacin plasma concentrations and QTc prolongation. The 900 mg dose was associated with more adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age.

Author: HooverRandall, HuntThomas, BenedictMichael, PaulsonSusan K, LawrenceLaura, CammarataSue, SunEugene

This report describes the pharmacokinetic parameters, safety profile, and tolerability of oral delafloxacin in two studies examining single and multiple ascending doses.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.

Author: LemaireSandrine, TulkensPaul M, Van BambekeFrançoise

Antibacterial activity
Intracellular efficacy

Delafloxacin, a novel fluoroquinolone with an anionic character, demonstrated high activity against Gram-positive bacteria, particularly in acidic environments, making it potentially advantageous for treating intracellular infections caused by Staphylococcus aureus.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy.

Author: Van BambekeFrançoise

Antibiotic treatment

Delafloxacin is a fluoroquinolone with high activity against Gram-positive organisms, anaerobes, and some fluoroquinolone-resistant strains. It is currently being evaluated for the treatment of complicated skin infections and community-acquired pneumonia.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization.

Author: LitwinJeffrey S, BenedictMichael S, ThornMichael D, LawrenceLaura E, CammarataSue K, SunEugene

Treatment of bacterial infections
Adverse events
QTc prolongation

Delafloxacin, given intravenously at 300 mg or 900 mg, did not prolong the QTc interval in healthy adults. The study found no relationship between delafloxacin plasma concentrations and QTc prolongation. The 900 mg dose was associated with more adverse events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Delafloxacin: A New Anti-methicillin-resistant Staphylococcus aureus Fluoroquinolone.

Author: SaravolatzLouis D, SteinGary E

Effective for skin infections
Favorable adverse event profile
MRSA activity

Delafloxacin, a new fluoroquinolone, is effective for acute bacterial skin and skin structure infections, including those caused by MRSA. It has a favorable safety profile compared to vancomycin and aztreonam combination therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

8.

Delafloxacin: First Global Approval.

Author: MarkhamAnthony

Antibacterial activity

Delafloxacin, a new fluoroquinolone antibiotic, was approved for the treatment of acute bacterial skin and skin structure infections. This article highlights the milestones in the development of delafloxacin, emphasizing its broad-spectrum activity against both gram-positive and gram-negative bacteria.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

The safety of treatment options for acute bacterial skin and skin structure infections.

Author: BassettiMatteo, PeghinMaddalena, CastaldoNadia, GiacobbeDaniele Roberto

Severe infection

This article discusses the choice of antibiotics for treating acute bacterial skin and skin-structure infections (ABSSSI) in both in-patients and out-patients. While many antibiotics have shown non-inferiority in efficacy, their safety profiles vary, making it crucial to consider these differences when selecting a treatment option.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Managing community acquired pneumonia in the elderly - the next generation of pharmacotherapy on the horizon.

Author: AmalakuhanB, EchevarriaK L, RestrepoM I

Treatment of CAP in elderly

This study reviews seven novel antibiotics currently in advanced stages of development for treating community-acquired pneumonia (CAP) in the elderly. The study evaluates the strengths and weaknesses of these antibiotics based on their ability to address specific challenges faced by elderly patients, such as compliance issues, immunosuppression, and polypharmacy. The findings highlight the potential of these antibiotics to improve treatment outcomes for CAP in this vulnerable population.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

13.

Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): Data from the Delafloxacin Phase 3 CABP Trial.

Author: McCurdySandra, NenningerAshley, SheetsAmanda, KeedyKara, LawrenceLaura, QuintasMegan, CammarataSue

Atypical activity
Broad-spectrum coverage
Treatment option for CABP

Delafloxacin, a new fluoroquinolone antibiotic, may be a suitable treatment option for community-acquired bacterial pneumonia (CABP) in adults, offering broad-spectrum coverage including activity against atypical pathogens. A clinical trial comparing delafloxacin to moxifloxacin found that delafloxacin had similar in vitro activity against Mycoplasma pneumoniae and greater activity against Legionella pneumophila.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

14.

Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization.

Author: RemyJoan M, Tow-KeoghCheryl A, McConnellTimothy S, DaltonJames M, DevitoJoseph A

MRSA treatment
Resistance development

Delafloxacin has excellent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA) and exhibits a low probability for the selection of resistant mutants.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.

Author: KocsisBela, DomokosJ, SzaboD

Antibacterial effect
Fluoroquinolones
Fluoroquinolone toxicity
Resistant pathogens

New fluoroquinolones such as avarofloxacin, delafloxacin, finafloxacin, and zabofloxacin are being studied in clinical trials and have shown enhanced antibacterial activity, even against ciprofloxacin-resistant pathogens.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

17.

A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms.

Author: BauerJulia, SialaWafi, TulkensPaul M, Van BambekeFrançoise

Effective against biofilms
None mentioned

This study developed a pharmacodynamic model to compare the effectiveness of different antibiotics against Staphylococcus aureus biofilms. The model showed that delafloxacin and daptomycin were the most effective against both young and mature biofilms, reducing bacterial viability by more than 50% at clinically achievable concentrations. Rifampin, tigecycline, and moxifloxacin were effective against mature MRSA biofilms, while oxacillin was effective against MSSA. Overall, the study highlights the potential utility of daptomycin and delafloxacin for the treatment of biofilm-related infections.

Evaluation StudyResearch that systematically evaluates the effectiveness of a particular program or policy. It measures its outcomes and provides important information for future decision-making.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

18.

Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Author: KaulG, KapoorE, DasguptaA, ChopraS

Skin infection treatment

Delafloxacin is a new fluoroquinolone antibiotic approved by the FDA to treat acute bacterial skin infections. It is effective against many types of bacteria, including methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones.

Author: Van BambekeFrançoise

Antibacterial activity
Hepatotoxicity
Visual disturbance

This review discusses the potential benefits of lipoglycopeptide, ketolide, and quinolone antibiotics currently in clinical development, highlighting their advantages over existing molecules within their respective classes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

22.

Clinical Pharmacokinetics and Pharmacodynamics of Delafloxacin.

Author: ShiuJennifer, TingGrace, KiangTony Kl

Bronchitis treatment
Gonorrhea treatment
Pneumonia treatment
Skin infection treatment
QTc prolongation

Delafloxacin is a newly approved antibiotic for treating acute bacterial skin infections. This review summarizes the drug's clinical pharmacology, including its absorption, distribution, metabolism, and excretion. The review also discusses the drug's efficacy and safety profile, highlighting its broad antibacterial activity and generally well-tolerated nature.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

23.

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.

Author: HooverRandall, MarburyThomas C, PrestonRichard A, QuintasMegan, LawrenceLaura E, PaulsonSusan K, LukeDavid R, CammarataSue K

Pneumonia treatment
Skin infection treatment

Delafloxacin is a new antibiotic effective against various bacteria, including methicillin-resistant Staphylococcus aureus. A study found that a single intravenous dose of delafloxacin was well tolerated in patients with mild, moderate, or severe liver impairment. Dose adjustments are not needed for patients with liver impairment.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Effects of Urine Matrix and pH on the Potency of Delafloxacin and Ciprofloxacin against Urogenic Escherichia coli and Klebsiella pneumoniae.

Author: SoWonhee, CrandonJared L, NicolauDavid P

Enhanced potency in acidic urine

Delafloxacin showed greater potency against urogenic Enterobacteriaceae in urine than ciprofloxacin. The potency of delafloxacin was enhanced in the acidic environment commonly observed in urinary tract infection.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

26.

A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin.

Author: KingsleyJeff, MehraPurvi, LawrenceLaura E, HenryEugenia, DuffyErin, CammarataSue K, PullmanJohn

ABSSSI treatment
Diarrhea
Nausea
Vomiting

Delafloxacin is a new investigational anionic fluoroquinolone being developed for treating infections caused by Gram-positive and -negative organisms. This Phase 2 trial evaluated the efficacy and safety of delafloxacin in patients with acute bacterial skin and skin structure infections (ABSSSIs). Delafloxacin showed significantly greater cure rates compared to vancomycin, particularly in obese patients. Cure rates were similar to linezolid. Delafloxacin was well tolerated, with the most common adverse events being nausea, diarrhea, and vomiting.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

27.

The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin.

Author: PaulsonSusan K, Wood-HorrallRebecca N, HooverRandall, QuintasMegan, LawrenceLaura E, CammarataSue K

Delafloxacin did not significantly change the pharmacokinetics of midazolam, except for a small but not clinically relevant change in the Cmax of midazolam.

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.